Ding Ziyang, Shi Run, Hu Weikang, Tian Lei, Sun Rong, Wu Yang, Zhang Xiaoyan
The Second Clinical School of Nanjing Medical University, Nanjing, China.
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Oncol. 2023 Sep 6;13:1193978. doi: 10.3389/fonc.2023.1193978. eCollection 2023.
Hematologic malignancies comprise a diverse range of blood, bone marrow, and organ-related disorders that present significant challenges due to drug resistance, relapse, and treatment failure. Cancer-associated fibroblasts (CAFs) represent a critical component of the tumor microenvironment (TME) and have recently emerged as potential therapeutic targets. In this comprehensive review, we summarize the latest findings on the roles of CAFs in various hematologic malignancies, including acute leukemia, multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms, and lymphoma. We also explore their involvement in tumor progression, drug resistance, and the various signaling pathways implicated in their activation and function. While the underlying mechanisms and the existence of multiple CAF subtypes pose challenges, targeting CAFs and their associated pathways offers a promising avenue for the development of innovative treatments to improve patient outcomes in hematologic malignancies.
血液系统恶性肿瘤包括多种与血液、骨髓及器官相关的疾病，由于耐药性、复发和治疗失败，这些疾病带来了重大挑战。癌症相关成纤维细胞（CAFs）是肿瘤微环境（TME）的关键组成部分，最近已成为潜在的治疗靶点。在这篇全面综述中，我们总结了关于CAFs在各种血液系统恶性肿瘤中的作用的最新发现，包括急性白血病、多发性骨髓瘤、慢性淋巴细胞白血病、骨髓增殖性肿瘤和淋巴瘤。我们还探讨了它们在肿瘤进展、耐药性以及涉及其激活和功能的各种信号通路中的作用。虽然潜在机制和多种CAF亚型的存在带来了挑战，但靶向CAFs及其相关通路为开发创新治疗方法以改善血液系统恶性肿瘤患者的预后提供了一条有前景的途径。
